Logo wahanariau.com
  2. Adagene

Adagene

Index
Globenewswire

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc

Kamis, 07 November 2024 - 22:30:00 Wib
Globenewswire

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Rabu, 09 Oktober 2024 - 17:30:00 Wib
Globenewswire

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Senin, 16 September 2024 - 14:30:00 Wib
Globenewswire

Adagene to Participate in Investor Conferences in September

Kamis, 29 Agustus 2024 - 18:30:00 Wib
Globenewswire

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update

Jumat, 26 Juli 2024 - 09:10:07 Wib
Globenewswire

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

Jumat, 12 Juli 2024 - 18:30:00 Wib